During 1987-1996, over 22,000 tuberculosis cases were reported in Texas, at an average annual incidence rate of 12.5 cases per 100,000 population. Counties with the highest rates were located along the Mexico-Texas border and in northwestern Texas. Nine percent of cases were resistant to at least one of the five first-line antituberculosis drugs used for treatment. Almost 5 percent (4.6%) were resistant to isoniazid, either alone or in combination with other antibiotics; 2.3% were resistant to rifampin; and only 1.3% were resistant to both isoniazid and rifampin. Being a recurrent case, being foreign-born, being 20-39 years of age, and residing in a Mexico-Texas border county were independent risk factors for isoniazid resistance and rifampin resistance. Tuberculosis patients with human immunodeficiency virus (HIV) infection were more likely to have rifampin resistance and less likely to have isoniazid resistance than patients without HIV infection. Factors associated with multi-drug-resistant tuberculosis included a history of previous tuberculosis (relative risk (RR) = 4.91, 95% confidence interval (Cl) 3.5-6.8), non-US birth (RR = 2.69, 95% Cl 2.1-3.5), age younger than 20 years (RR = 1.97, 95% Cl 1.1-3.5), age 20-39 years (RR = 1.82, 95% Cl 1.3-2.6), and residence in a Mexico-Texas border county (RR = 2.33, 95% Cl 1.8-3.1). Am J Epidemiol 1999; 149:359-65. drug resistance; risk factors; tuberculosis
After years of decline, tuberculosis, caused by Mycobacterium tuberculosis, is considered a reemerging disease in the United States. The resurgence of this bacterial infection has been mainly associated with the human immunodeficiency virus (HTV) epidemic and immigration from high-prevalence countries (1) . The initial treatment of tuberculosis involves administration of four drugs-isoniazid, rifampin, pyrazinamide, and either ethambutol or streptomycin-until drug susceptibility test results are obtained (2) . Two of the five drugs, isoniazid and rifampin, are critical in successfully treating tuberculosis (3) . Pyrazinamide, ethambutol, and streptomycin are added to shorten the duration of therapy and to prevent the emergence of drug-resistant bacteria. Drug resistance develops from natural mutations, from noncompliance with prescribed therapy, and from inadequate antituberculosis treatment (4, 5) . Drug resistance extends the duration of therapy from 6 months to 24 months or longer and is associated with a lower cure rate (3, 6) . Resistant strains of M. tuberculosis threaten the success of patient treatment and control programs.
Recent studies of drug-resistant tuberculosis in the United States have reported overall drug resistance rates of 13-33 percent (7) (8) (9) . Several nosocomial outbreaks of multiple-drug-resistant tuberculosis-strains of M. tuberculosis that are resistant to both isoniazid and rifampin-have also been reported (10, 11) . Although drug-resistant tuberculosis is widespread, most studies in the United States have focused on limited populations such as residents of New York City, residents of small geographic areas, or patients receiving treatment at a single medical center (7, (12) (13) (14) . These studies may not provide an accurate measure of the prevalence of drugresistant tuberculosis in the United States as a whole or in a specific state. Two separate nationwide surveys reported that approximately 14 percent of tuberculosis patients had isolates resistant to one or more drugs (8, 9) . Few studies have addressed risk factors associated with drug resistance (7) (8) (9) . Resistance to antituberculosis medication has been associated with previous tuberculosis, HTV infection, injection drug use, foreign birth, race/ethnicity, and age. To our knowledge, no statewide population-based study of drug-resistant tuberculosis has been conducted. This report describes the magnitude of, demography of, and secular trend in drugresistant tuberculosis in Texas. Annually, over 9 percent of US tuberculosis cases occur in Texas residents (15) . Texas are reported to the  Tuberculosis Elimination Division of the Texas  Department of Health (Austin, Texas) by physicians, laboratories, hospitals, local health departments, and other medical facilities. We reviewed the following data for cases reported from January 1, 1987, through December 31, 1996: name; date of birth; sex; race/ethnicity; country of origin; date of positive culture; city and county of residence; date of report; antibiotic susceptibility; predominant site of infection; histories of incarceration, drug abuse, and homelessness; history of previous tuberculosis; and evidence of HIV infection.
MATERIALS AND METHODS

Tuberculosis cases in
In Texas, a case of tuberculosis must meet the following criteria: laboratory confirmation of the presence of M. tuberculosis or, in the absence of laboratory confirmation, 1) a positive tuberculin skin test reaction, 2) other signs and symptoms compatible with tuberculosis, such as an abnormal, unstable chest radiograph or clinical or pathologic evidence of current disease, and 3) treatment with two or more antituberculosis medications.
Multi-drug-resistant tuberculosis was defined as culture-confirmed tuberculosis with organisms resistant to at least isoniazid and rifampin. Patients for whom susceptibility test results were not available or were not performed were excluded from statistical analysis.
When information on a specific item was not available, the case was excluded from analysis for that specific variable. Relative risks were calculated and tests for trend were carried out using the Epi Info software program (Centers for Disease Control and Prevention, Atlanta, Georgia). Linear regression analyses were performed using Statistix (Analytical Software, Tallahassee, Florida) to identify the independent risk factors associated with drug resistance. Linear risk models were calculated for three risks: isoniazid resistance, rifampin resistance, and multiple drug resistance. Risk factors included in the regression models for each resistance category were age (<20, 20-39, 40-59, and >60 years), sex, race/ethnicity (white, Asian, African-American, or Hispanic), residence in a Mexico-Texas border county, birth outside of the United States, infection with HIV, histories of incarceration, drug abuse, and homelessness, and history of previous tuberculosis. Age was entered as three design variables with age >60 years used as the reference category. Race/ethnicity was also entered as three design variables, with whites used as the reference group. These risk factors were selected for evaluation because other reports have suggested that they may be associated with drug resistance, or because they were statistically significant in univariate analysis. Because relative risks adjusted for multiple risk factors were similar to the unadjusted risks, only unadjusted risks are shown in table 2. Instances where adjustment did make a difference are noted in the text. A probability of <0.05 was chosen for statistical significance. Incidence rates were calculated utilizing 1990 population data obtained from the US Census Bureau.
RESULTS
During the years 1987-1996, 22,257 cases of tuberculosis were reported in Texas. The number of cases reported annually ranged from 1,757 in 1987 to 2,542 in 1994. The average annual incidence rate was 12.5 cases per 100,000 population. Most patients were males (68 percent) and ranged in age from 20 through 59 years (65 percent). In addition, most were Hispanic (40 percent) or African-American (27 percent). Annual incidence rates (cases per 100,000 population) for whites ranged from 4.4 to 5.8; rates for African Americans ranged from 23.0 to 34.9; and rates for Hispanics ranged from 15.6 to 23.6. A least one patient with tuberculosis resided in 237 of the 254 counties in Texas. Harris County (containing the city of Houston) was the county of residence for 6,294 cases (28.3 percent). Counties with the highest average annual incidence rates were located along the Mexico-Texas border and in rural northwestern Texas.
Drug susceptibility results were available for 17,425 patients. Demographic characteristics of patients for whom susceptibility results were available were similar to those of patients without available results. Nine percent of the cases were resistant to at least one of the five first-line antituberculosis drugs used for treatment: isoniazid, rifampin, ethambutol, pyrazinamide, and streptomycin. Resistance to isoniazid, either alone or in combination with other antibiotics, occurred in 4.6 percent of the cases. Rifampin resistance was noted in 2.3 percent of the cases. Resistance to streptomycin and resistance to ethambutol was reported for 5.0 percent and 1.1 percent of the cases, respectively. Resistance to both streptomycin and isoniazid (336 patients) was the most common pattern of resistance to two or more drugs, followed by resistance to isoniazid and rifampin (236 patients). Resistance to three or more first-line drugs was reported in 13 percent of cases with drug resistance.
Annually, the percentage of cases with drug resistance ranged from 7.6 to 10.8. The percentage of cases with drug resistance decreased over time from 10.7 percent in 1987 to 8.9 percent in 1996 (test for trend: p < 0.0004). resistance to one or more drugs, followed by Hispanics (10.8 percent), whites (7.4 percent), and African Americans (6.6 percent). Drug resistance was seen more frequently in patients with a history of tuberculosis (recurrent cases) and in patients bom outside of the United States. Overall, 4.2 percent of the patients reported a history of previous tuberculosis. Approximately 25 percent of the patients had been born outside of the United States. Most of the foreign-bom patients had been bom in Mexico (62 percent), followed by those bom in Vietnam (12 percent) and the Philippines (4 percent). Resistance was reported in 15.0 percent of patients who were foreign-bom compared with 7.4 percent of US-bom patients. A total of 2,221 tuberculosis patients were coinfected with HTV. Only 9.3 percent of these patients had drug resistance. A similar percentage (9.1 percent) of tuberculosis patients without evidence of HTV infection had drug resistance.
Isoniazid resistance
A total of 806 (4.6 percent) patients had isoniazid resistance. Annually, the percentage of cases with isoniazid resistance ranged from 4.1 percent to 5.6 percent. For the time period studied, no secular trend of increasing or decreasing prevalence of isoniazid resistance was noted. Patients with isoniazid resistance resided throughout the state. A total of 114 of the 254 counties in Texas had 10 or more tuberculosis cases. In these 114 counties, the percentage of cases with isoniazid resistance was <2 percent in 32 counties and >4 percent in 61 counties.
Percentages of patients with isoniazid resistance and relative risks for isoniazid resistance are presented in tables 1 and 2, respectively, according to various demographic and lifestyle characteristics. Relative risks were similar for males and females unless otherwise noted. Residence in a Mexico-Texas border county was associated with isoniazid resistance. A high percentage (93.2 percent) of patients residing in border counties were Hispanic. Hispanics with tuberculosis who resided in border counties were more likely to have isoniazid resistance (7.2 percent) than Hispanic patients residing in nonborder counties (5.0 percent) (relative risk (RR) = 1.45, 95 percent (CI) 1.19-1.76). Patients between 20 and 39 years of age were more likely to have isoniazid resistance than cases aged 60 years or older. Hispanics and Asians were more likely to have isoniazid-resistant tuberculosis than whites. African Americans were less likely to have isoniazidresistant tuberculosis.
Isoniazid resistance was associated with having a history of tuberculosis (recurrent cases) and with being bom outside of the United States. Resistance to isoniazid was reported in 7.8 percent, 13.3 percent, and 14.1 percent of patients bom in Mexico, Vietnam, and the Philippines, respectively. Most Asians with isoniazid resistance (88.3 percent) were foreign-born. Almost half (44.8 percent) of the isoniazid-resistant Hispanics were foreign-bom. Among Hispanics, foreign birth was also associated with isoniazid resistance (RR = 1.88, 95 percent CI 1.54-2.30).
Isoniazid resistance was more common (4.8 percent) in tuberculosis patients without HTV infection than those with HTV infection (3.2 percent). Isoniazid resistance was more common in patients with a history of incarceration. The association with incarceration was observed for males (RR = 1.49, 95 percent CI 1.19-1.87) but not for females (RR = 0.59, 95 percent CI 0.22-1.57). Among males, the association of isoniazid resistance with history of incarceration was observed only in African Americans (RR = 2.46, 95 percent CI 1.68-3.61). No association for isoniazid resistance was observed in those with a history of drug abuse. Patients with a history of homelessness were less likely to have isoniazid resistance. In multiple regression analysis, Mexico-Texas border residence, age, Asian and African-American race/ethnicity, history of tuberculosis, foreign birth, HTV infection, and history of incarceration remained significant predictors of isoniazid resistance. When adjusted for all other factors, Hispanic ethnicity, male sex, and history of homelessness were no longer associated with isoniazid resistance.
Rifampin resistance
A total of 399 (2.3 percent) patients had rifampin resistance. Annually, rifampin resistance ranged from 1.5 percent to 2.8 percent. No trend of increasing or decreasing prevalence of rifampin resistance was noted. Patients with rifampin resistance resided in 66 counties throughout Texas. Similar to isoniazid resistance, rifampin resistance was associated with residing in a Mexico-Texas border county, being younger, being Hispanic, being a recurrent case, and being foreign-born (table 2) . Unlike isoniazid resistance, rifampin resistance was not associated with Asian or African-American race/ethnicity or history of incarceration.
Rifampin resistance in Hispanics showed an annual trend of decreasing prevalence from 3.8 percent in 1987 to 2.4 percent in 1996 (test for trend: p = 0.03). No secular trend was observed for whites or for African Americans. Foreign-born Hispanics with tuberculosis had more rifampin resistance (4.0 percent) than did US-born Hispanics (1.8 percent) (OR = 2.23, 95 percent Cl 1.66-3.01).
Tuberculosis patients with HTV infection were more likely to have rifampin resistance than were patients without HTV coinfection. Overall, 4.2 percent of tuberculosis patients who were coinfected with HTV had rifampin resistance, as compared with 2 percent of tuberculosis patients without HTV infection. No association with rifampin resistance was observed for histories of incarceration, homelessness, or drug abuse.
Except for Hispanic ethnicity, the same factors found to be predictors in univariate analysis-residence in a Mexico-Texas border county, age less than 60 years, history of previous tuberculosis, foreign birth, and HTV infection-remained significant predictors in multivariate analysis.
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Multiple drug resistance A total of 236 patients (1.3 percent) had resistance to both isoniazid and rifampin, or multiple drug resistance, either alone (75 cases) or in combination with resistance to the other three first-line drugs (161 cases). Ten patients were resistant to all five first-line antituberculosis antibiotics. No nosocomial outbreak or prison outbreak of multi-drug-resistant tuberculosis was identified during this time period. From 1987 to 1991, 1.7 percent of patients were resistant to multiple antituberculosis drugs. From 1992 through 1996, 1.1 percent of patients were multi-drug-resistant. A secular trend of decreasing incidence of multiple drug resistance was noted (test for trend: p = 0.002).
The 236 patients with multiple drug resistance resided in 53 counties throughout the state. The occurrence of multiple drug resistance was higher in Hispanics (1.8 percent) and Asians (2.1 percent) than in whites. The percentage of African Americans with multiple drug resistance was similar to that of whites. All 25 Asians with multi-drug-resistant tuberculosis were foreign-born. No US-born Asian had multi-drugresistant tuberculosis.
Over 5 percent (5.7 percent) of patients with recurrent tuberculosis were multi-drug-resistant, compared with 1.2 percent of patients with new cases. Only 1.0 percent of US-born patients had multi-drug-resistant tuberculosis, compared with 2.6 percent of foreignbom patients. Multiple drug resistance was reported in 2.8 percent of patients born in Mexico, 1.7 percent of patients bom in Vietnam, and 4.0 percent of patients bom in the Philippines.
In univariate and multivariate analyses, multiple drug resistance was associated with residing in a MexicoTexas border county, being in a younger age group, being a recurrent case, and being foreign-bom. The association of Asian or Hispanic ethnicity with multiple drug resistance was explained by other risk factors.
DISCUSSION
Demographic and lifestyle characteristics associated with drug-resistant tuberculosis in Texas included a history of previous tuberculosis, non-US birth, younger age, and residence in a Mexico-Texas border county. Other characteristics, such as HTV infection and history of incarceration, were important in the occurrence of rifampin resistance and isoniazid resistance, respectively. Although race/ethnicity was important in the occurrence of isoniazid resistance, it was not important in rifampin resistance or multiple drug resistance.
Several of the characteristics that contribute to drug resistance in Texas have been previously identified as risk factors in other studies. Increased drug resistance among recurrent cases and among patients bom outside of the United States has been previously reported (7-9, 14, 16) . Efforts to control drug-resistant tuberculosis must continue to address the issues of inappropriate therapy and patient noncompliance, which contribute to the failure of initial therapy in eliminating disease. Foreign-bom populations living in Texas and throughout the United States will continue to be important in attempts to address drug-resistant tuberculosis.
The associations of drug resistance with race/ethnicity and age have not been consistently noted. A higher prevalence of resistance has been reported for Asians and Hispanics in the United States as a whole (16) ; in New York City, however, multiple drug resistance was associated with being white (17) . In Texas, rifampin resistance and multiple drug resistance were not associated with race/ethnicity. In regression analyses, the possible associations of rifampin and multiple drug resistance with being Hispanic or Asian that were found in univariate analysis were eventually explained by other factors. Isoniazid resistance, however, was associated with African-American and Asian ethnicity. Higher levels of drug resistance in younger age groups have been previously reported, but other studies have found no association with age (16, (18) (19) (20) . A recent nationwide survey found isoniazid resistance to be more common in younger age groups (9) . Younger age groups in Texas were also more likely to have isoniazid-resistant, rifampinresistant, and multi-drug-resistant tuberculosis.
New York City has been recognized as a geographic area with high levels of drug resistance (7-9, 12, 17) . An earlier study commented on the significant amount of drug-resistant tuberculosis in Texas (19) . The present study provides a more thorough review of drug resistance in Texas in comparison with that study. The prevalence of drug-resistant tuberculosis in Texas is lower than prevalences reported for the United States generally (9) . The perception that Texas must have more drug-resistant tuberculosis because Texas borders a foreign country was not confirmed. Although residence in a Mexico-Texas border county was a risk factor for drug-resistant tuberculosis, the prevalence of resistance in border counties was lower than or similar to that reported for the United States as a whole (9) .
In New York City, 36.7 percent of tuberculosis patients are coinfected with HTV (17) . Approximately 20-30 percent of New York City tuberculosis patients who are coinfected with HTV have resistance to isoniazid; 16-19 percent have multiple drug resistance (13, 17) . HTV infection was identified as a risk factor for isoniazid resistance and multiple drug resistance in New York City (17) . Approximately 10 percent of the tuber-culosis patients in Texas are coinfected with HIV. In Texas, only 1 percent of tuberculosis patients with HTV have multi-drug-resistant tuberculosis. ForTexans, HTV infection was associated with an increased risk of rifampin resistance. Unlike tuberculosis patients with HTV infection in New York City, no increased risk for isoniazid resistance or multiple drug resistance was seen in Texas (7) . Resistance to these drugs in the tuberculosis patients with HTV infection in Texas was not seen at the same level as that reported in other populations (13) . Malabsorption of rifampin and prophylactic use of rifabutin for Mycobacterium avium infection have been suggested as possible factors contributing to rifampin resistance in tuberculosis patients with HTV infection (21) . The various prevalences of drug resistance seen in HTV patients may be related to regional transmission of different strains of M. tuberculosis among these populations.
A recent report described drug resistance in the New York State prison population (22) . Almost one third (32 percent) of the New York State prison inmates with tuberculosis had multiple drug resistance. However, a history of incarceration was not identified as a risk factor for drug resistance among New York City tuberculosis patients (17) . In Texas, only 1.5 percent of tuberculosis patients with a history of incarceration had multiple drug resistance. This low prevalence is probably a reflection of the overall lower level of drug resistance in Texas. The high level of multi-drugresistant tuberculosis in the New York State prison population may also be associated with outbreaks involving multi-drug-resistant strains. No multi-drugresistant tuberculosis outbreak has occurred in Texas prisons. Texas tuberculosis patients with a history of incarceration are more likely to have isoniazid resistance than patients without a history of incarceration. The association of incarceration with isoniazid resistance was seen only among African-American males. More detailed studies are needed to ascertain why a history of incarceration is associated with isoniazid resistance in African-American males and not in males of other races/ethnicities.
In general, the magnitude of drug resistance in Texas is lower than that in other geographic areas (7, 13, 14, 16, 18, 23) . The prevalence of isoniazid resistance and rifampin resistance in Texas is much lower than that in New York City, where 26 percent of cases have isoniazid resistance and 22 percent have rifampin resistance (7) . Multiple drug resistance in Texas (1.3 percent) is lower than that in the United States as a whole (2.2 percent) and much lower than the 13 percent reported for New York City for 1994 (17) . In 1991, only 13 states reported having multi-drug-resistant tuberculosis cases. Ten states had higher prevalence rates than did Texas (8) . The variability in prevalence could be due to different time periods' being studied or to studies' being based on patients from single medical centers or on populations of small geographic areas.
Overall, no secular trend of increasing or decreasing prevalence of isoniazid or rifampin resistance was noted in Texas, although a decreasing prevalence of rifampin resistance was observed for Hispanics. No increase in multiple drug resistance was ever observed in Texas. Since 1987, multiple drug resistance has decreased over time in Texas, which is consistent with a national trend. Previous studies in New York City have noted an increasing prevalence of resistance to isoniazid or rifampin over time (7, 12) . From 1987 to 1991, isoniazid resistance, rifampin resistance, and multiple drug resistance all showed a significant increase in New York City. From 1991 to 1994, the percentage of cases with resistance to these drugs decreased (17) . Similarly, from 1993 to 1996 in the United States, isoniazid resistance, rifampin resistance, and multiple drug resistance decreased over time (9) .
Measures designed to prevent drug resistance should be focused on recognized risk groups. In Texas, risk groups for isoniazid resistance, rifampin resistance, and multiple drug resistance include persons with recurrent tuberculosis, those bom outside of the United States, and those aged 20-39 years. An important risk factor for drug resistance in Texas was residence in a Mexico-Texas border county. Control of drug-resistant tuberculosis along the Mexico-Texas border may require a binational effort.
